Conference Track

Chronic Lymphocytic Leukemia

Source: CCO Independent Conference Coverage of the American Society of Hematology 2011 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Outcomes in CLL Following Initial Therapy With Fludarabine vs Chlorambucil Differ Depending on Age
Rituximab Plus Lenalidomide Active, Well Tolerated in Both Younger and Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Rituximab Plus Chlorambucil Induction Therapy Active, Well Tolerated in Elderly Patients With Previously Untreated CLL
In Patients With CLL Receiving FCR, Cytogenetic Analysis Plus MRD Detection Identifies High Risk of Progression
Lenalidomide and Rituximab Combination Therapy Active With Durable Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia
Ofatumumab Plus Lenalidomide Active, Well Tolerated in Relapsed Chronic Lymphocytic Leukemia
CC-5013-CLL-009: Lenalidomide Active, Well Tolerated at Different Starting Doses in Relapsed or Refractory Chronic Lymphocytic Leukemia
Obatoclax Plus Fludarabine/Rituximab Is Well Tolerated and Active in Patients With Relapsed CLL/SLL
Fludarabine, Bendamustine, and Rituximab Chemoimmunotherapy Active in Previously Treated Patients With CLL: Results of a Phase I Study
Ofatumumab Shows Promising Activity and Is Well Tolerated in Previously Untreated Older Patients With CLL or SLL

CCO Slideset

Chronic Lymphocytic Leukemia

Faculty:

John C. Byrd, MD
Kanti Rai, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Interpret new data on novel agents and therapeutic approaches with potential importance in the treatment of patients with chronic lymphocytic leukemia
Integrate new agents and treatment strategies into the clinical management of patients with chronic lymphocytic leukemia
Discuss with patients clinical trials of novel agents for chronic lymphocytic leukemia for which they may be eligible
Nurses will be better able to provide appropriate care and counsel for patients and their families

Topics covered include:

Strategies for Frontline Therapy in Older Patients
Approaches for Relapsed/Refractory Disease
Novel Agents

CREDIT INFORMATION

Release Date: 2/16/12

Expiration Date: 2/15/13

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.